PL2554541T3 - Środek terapeutyczny lub środek profilaktyczny na fibromialgię - Google Patents
Środek terapeutyczny lub środek profilaktyczny na fibromialgięInfo
- Publication number
- PL2554541T3 PL2554541T3 PL11765736T PL11765736T PL2554541T3 PL 2554541 T3 PL2554541 T3 PL 2554541T3 PL 11765736 T PL11765736 T PL 11765736T PL 11765736 T PL11765736 T PL 11765736T PL 2554541 T3 PL2554541 T3 PL 2554541T3
- Authority
- PL
- Poland
- Prior art keywords
- agent
- fibromyalgia
- prophylactic
- therapeutic agent
- therapeutic
- Prior art date
Links
- 208000001640 Fibromyalgia Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010083721 | 2010-03-31 | ||
| EP11765736.1A EP2554541B1 (en) | 2010-03-31 | 2011-03-31 | Therapeutic agent or prophylactic agent for fibromyalgia |
| PCT/JP2011/058218 WO2011125836A1 (ja) | 2010-03-31 | 2011-03-31 | 線維筋痛症の治療剤又は予防剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2554541T3 true PL2554541T3 (pl) | 2016-06-30 |
Family
ID=44762774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11765736T PL2554541T3 (pl) | 2010-03-31 | 2011-03-31 | Środek terapeutyczny lub środek profilaktyczny na fibromialgię |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8957094B2 (pl) |
| EP (1) | EP2554541B1 (pl) |
| JP (1) | JP5751168B2 (pl) |
| KR (1) | KR101738471B1 (pl) |
| CN (1) | CN102822148B (pl) |
| AU (1) | AU2011237072B2 (pl) |
| BR (1) | BR112012022947B1 (pl) |
| CA (1) | CA2793709C (pl) |
| ES (1) | ES2562470T3 (pl) |
| MX (1) | MX2012010767A (pl) |
| PL (1) | PL2554541T3 (pl) |
| RU (1) | RU2560168C2 (pl) |
| WO (1) | WO2011125836A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012024346A2 (pt) * | 2010-04-28 | 2016-05-24 | Toray Industries | agente terapêutico ou agente profilático para a doença de alzheimer |
| KR101786818B1 (ko) | 2010-07-30 | 2017-10-18 | 도레이 카부시키가이샤 | 신경장애성 동통의 치료제 또는 예방제 |
| JPWO2014088106A1 (ja) * | 2012-12-06 | 2017-01-05 | 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ | 線維筋痛症の予防または治療薬 |
| JP6447496B2 (ja) | 2014-01-29 | 2019-01-09 | 東レ株式会社 | 多発性硬化症の治療剤又は予防剤 |
| EP3328819B1 (en) * | 2015-07-28 | 2020-04-01 | Beta Cat Pharmaceuticals, Inc. | Anthracene-9, 10-dione dioxime compounds prodrugs and their uses |
| WO2017096148A1 (en) * | 2015-12-03 | 2017-06-08 | Katz Robert S | Methods and systems for diagnosing and treating fibromyalgia |
| EP3492452B1 (en) | 2016-07-29 | 2022-08-31 | Japan Tobacco Inc. | Production method for pyrazole-amide compound |
| WO2018181859A1 (ja) * | 2017-03-31 | 2018-10-04 | 東レ株式会社 | 抗がん剤誘発末梢神経障害の治療剤又は予防剤 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP608898A0 (en) * | 1998-09-23 | 1998-10-15 | Fujisawa Pharmaceutical Co., Ltd. | New use of prostaglandin E2 antagonists |
| US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
| WO2000066562A1 (en) * | 1999-05-03 | 2000-11-09 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
| US20040122008A1 (en) | 2002-09-05 | 2004-06-24 | Protter Andrew A. | Treatment of pain by inhibition of p38 MAP kinase |
| CN101454299A (zh) * | 2006-03-27 | 2009-06-10 | 东丽株式会社 | 酰脲衍生物及其医药用途 |
| JP2010503656A (ja) * | 2006-09-13 | 2010-02-04 | アストラゼネカ アクチボラグ | スピロ−オキサゾリジノン化合物と代謝共役型グルタミン酸受容体ポテンシエーターとしてのその使用 |
| US20080171762A1 (en) * | 2007-01-16 | 2008-07-17 | Ockert David M | Treatment of pain with naloxone |
| WO2008105383A1 (ja) | 2007-02-26 | 2008-09-04 | Toray Industries, Inc. | ピラゾール誘導体およびその医薬用途 |
| TWI435874B (zh) * | 2008-10-31 | 2014-05-01 | Toray Industries | 環己烷衍生物及其醫藥用途 |
-
2011
- 2011-03-31 ES ES11765736.1T patent/ES2562470T3/es active Active
- 2011-03-31 RU RU2012146325/04A patent/RU2560168C2/ru not_active IP Right Cessation
- 2011-03-31 BR BR112012022947-8A patent/BR112012022947B1/pt not_active IP Right Cessation
- 2011-03-31 MX MX2012010767A patent/MX2012010767A/es active IP Right Grant
- 2011-03-31 CN CN201180016967.3A patent/CN102822148B/zh not_active Expired - Fee Related
- 2011-03-31 CA CA2793709A patent/CA2793709C/en active Active
- 2011-03-31 PL PL11765736T patent/PL2554541T3/pl unknown
- 2011-03-31 KR KR1020127023059A patent/KR101738471B1/ko not_active Expired - Fee Related
- 2011-03-31 JP JP2011514905A patent/JP5751168B2/ja not_active Expired - Fee Related
- 2011-03-31 AU AU2011237072A patent/AU2011237072B2/en not_active Ceased
- 2011-03-31 WO PCT/JP2011/058218 patent/WO2011125836A1/ja not_active Ceased
- 2011-03-31 US US13/636,805 patent/US8957094B2/en active Active
- 2011-03-31 EP EP11765736.1A patent/EP2554541B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012010767A (es) | 2012-10-15 |
| JPWO2011125836A1 (ja) | 2013-07-11 |
| CN102822148B (zh) | 2015-03-11 |
| CN102822148A (zh) | 2012-12-12 |
| US8957094B2 (en) | 2015-02-17 |
| EP2554541A4 (en) | 2013-10-09 |
| EP2554541B1 (en) | 2015-12-09 |
| BR112012022947A2 (pt) | 2020-07-28 |
| WO2011125836A1 (ja) | 2011-10-13 |
| RU2012146325A (ru) | 2014-05-10 |
| CA2793709A1 (en) | 2011-10-13 |
| AU2011237072B2 (en) | 2014-09-04 |
| EP2554541A1 (en) | 2013-02-06 |
| BR112012022947B1 (pt) | 2021-06-15 |
| CA2793709C (en) | 2017-09-12 |
| KR101738471B1 (ko) | 2017-05-22 |
| ES2562470T3 (es) | 2016-03-04 |
| JP5751168B2 (ja) | 2015-07-22 |
| AU2011237072A1 (en) | 2012-10-18 |
| KR20130052536A (ko) | 2013-05-22 |
| RU2560168C2 (ru) | 2015-08-20 |
| US20130190503A1 (en) | 2013-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201409186B (en) | Therapeutic agent or prophylactic agent for dementia | |
| RS67768B1 (sr) | Terapijski agens koji indukuje citotoksičnost | |
| IL222481A0 (en) | Combination therapy | |
| EP2552323A4 (en) | COMBINATION THERAPY | |
| IL226181A0 (en) | inhaler | |
| EP2510949A4 (en) | THERAPEUTICS FOR FIBROMYALGIA | |
| EP2554541A4 (en) | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR FIBROMYALGIA | |
| PL2529739T3 (pl) | Środek terapeutyczny lub profilaktyczny na choroby dróg żółciowych | |
| PL2723344T3 (pl) | Złożony środek leczniczy zawierający monoterpen | |
| IL245995A0 (en) | Prophylactic or medical agent for fibrosis | |
| IL220850B (en) | Anti- or alleviation of pigmentation | |
| ZA201206957B (en) | Sterilising apparatus | |
| PL2599487T3 (pl) | Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu | |
| GB201005394D0 (en) | Therapy | |
| GB201016864D0 (en) | Therapeutic methods | |
| PL2637748T3 (pl) | Armatura bezpieczeństwa | |
| EP2629766A4 (en) | COMBINATION THERAPY | |
| IL226574A (en) | Processes for making anamines | |
| GB201003727D0 (en) | Therapeutic agent | |
| GB201011456D0 (en) | Compositions and methods for embolization therapy | |
| GB201018104D0 (en) | Projection apparatus | |
| GB201119761D0 (en) | Examing procedure |